BrainsWay FY2024 EPS Forecast Boosted by Northland Capmk

BrainsWay Ltd. (NASDAQ:BWAY) – Equities research analysts at Northland Capmk raised their FY2024 earnings estimates for shares of BrainsWay in a report issued on Tuesday, November 12th. Northland Capmk analyst C. Byrnes now expects that the company will post earnings per share of $0.06 for the year, up from their prior estimate of $0.05. The consensus estimate for BrainsWay’s current full-year earnings is $0.05 per share.

BWAY has been the subject of a number of other research reports. Northland Securities increased their target price on shares of BrainsWay from $11.00 to $12.50 and gave the stock an “outperform” rating in a research report on Thursday, October 3rd. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of BrainsWay in a research report on Monday, October 21st.

BrainsWay Stock Down 4.3 %

Shares of BrainsWay stock opened at $9.12 on Thursday. The stock has a market capitalization of $152.12 million, a P/E ratio of 91.21 and a beta of 1.25. The company has a 50-day simple moving average of $9.23 and a 200 day simple moving average of $7.46. BrainsWay has a 12-month low of $4.30 and a 12-month high of $10.98.

BrainsWay (NASDAQ:BWAY) last announced its earnings results on Tuesday, November 12th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03. The business had revenue of $10.50 million during the quarter, compared to analysts’ expectations of $10.07 million. BrainsWay had a net margin of 3.88% and a return on equity of 3.52%. During the same quarter last year, the company posted ($0.01) EPS.

Institutional Investors Weigh In On BrainsWay

Several institutional investors have recently modified their holdings of BWAY. Virtu Financial LLC bought a new position in BrainsWay during the 1st quarter worth approximately $60,000. Rhumbline Advisers boosted its stake in BrainsWay by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock worth $110,000 after acquiring an additional 1,695 shares during the last quarter. Perritt Capital Management Inc bought a new position in BrainsWay in the second quarter valued at approximately $121,000. Good Life Advisors LLC lifted its stake in BrainsWay by 65.5% in the third quarter. Good Life Advisors LLC now owns 55,800 shares of the company’s stock valued at $516,000 after buying an additional 22,080 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its stake in BrainsWay by 583.2% in the first quarter. Acadian Asset Management LLC now owns 175,416 shares of the company’s stock valued at $923,000 after buying an additional 149,740 shares in the last quarter. Institutional investors and hedge funds own 30.11% of the company’s stock.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.